Jianchun Duan, Yun Zhang, Ran Chen, Liang Liang, Yi Huo, Shun Lu, Jun Zhao, Chunhong Hu, Yuping Sun, Kunyu Yang, Mingwei Chen, Yan Yu, Jianming Ying, Ruiqi Huang, Xiaopeng Ma, Shiangjiin Leaw, Fan Bai, Zhirong Shen, Shangli Cai, Daming Gao, Jie Wang, Zhijie Wang
The RATIONALE-307 study (ClinicalTrials.gov: NCT03594747) demonstrates prolonged progression-free survival (PFS) with first-line tislelizumab plus chemotherapy versus chemotherapy in advanced lung squamous cell carcinoma (LUSC; N = 360). Here we describe an immune-related gene expression signature (GES), composed of genes involved in both innate and adaptive immunity, that appears to differentiate tislelizumab plus chemotherapy PFS benefit versus chemotherapy. In contrast, a tislelizumab plus chemotherapy PFS benefit is observed regardless of programmed death ligand 1 (PD-L1) expression or tumor mutational burden (TMB)...
November 28, 2023: Cell reports medicine